About

Jose “Pepe” Carmona has served as ADC Therapeutics' Chief Financial Officer since December 2022. He previously served as Chief Financial Officer of Rubius Therapeutics (2020-2022) and of Radius Health (2017-2020), and before that as Chief Financial Officer of Innocoll Holdings and of Alcon Europe, Middle East & Africa, a division of Novartis, after numerous financial management positions of increasing responsibility at Novartis. Mr. Carmona holds a B.S. in industrial civil engineering from Universidad Tecnica Federico Santa Maria and an M.B.A. from Columbia Business School.

Roles

ADC Therapeutics SA
Chief Financial Officer · Current role
December 2022–present
ADC Therapeutics
Chief Financial Officer
December 2022 - present
Rubius Therapeutics
Chief Financial Officer
October 2020 - November 2022
Radius Health
Chief Financial Officer
May 2017 - September 2020
Innocoll Holdings
Chief Financial Officer
Alcon (Novartis division)
Chief Financial Officer, Europe, Middle East & Africa

External Roles

Senda Biosciences
Board member
HotSpot Therapeutics
Board member

Fixed Compensation

FY 2025
Salary
$525,208
ComponentAnnual base salary earned in fiscal 2025
All other compensation
$7,140
ComponentHealth, life and disability insurance, 401(k) matching contributions and other wellness benefits
Total compensation
$1,247,003

Performance Compensation

Data from FY 2025

Cash incentive

Non-equity incentive plan compensation
$328,255
Target Opportunity
PlanAnnual cash incentive under the ADC Therapeutics Annual Bonus Plan

Stock awards

Stock awards
$386,400
FormRestricted stock units (RSUs), ASC 718 grant-date fair value

Also at ADC Therapeutics SA

Related

See how VectorShift works for your firm

Request Demo